These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 12967471)

  • 21. Chimeric VEGF-E(NZ7)/PlGF promotes angiogenesis via VEGFR-2 without significant enhancement of vascular permeability and inflammation.
    Zheng Y; Murakami M; Takahashi H; Yamauchi M; Kiba A; Yamaguchi S; Yabana N; Alitalo K; Shibuya M
    Arterioscler Thromb Vasc Biol; 2006 Sep; 26(9):2019-26. PubMed ID: 16794222
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential expression of VEGF ligands and receptors in prostate cancer.
    Woollard DJ; Opeskin K; Coso S; Wu D; Baldwin ME; Williams ED
    Prostate; 2013 May; 73(6):563-72. PubMed ID: 23038639
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D.
    Davydova N; Harris NC; Roufail S; Paquet-Fifield S; Ishaq M; Streltsov VA; Williams SP; Karnezis T; Stacker SA; Achen MG
    J Biol Chem; 2016 Dec; 291(53):27265-27278. PubMed ID: 27852824
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intracranial meningiomas, the VEGF-A pathway, and peritumoral brain oedema.
    Nassehi D
    Dan Med J; 2013 Apr; 60(4):B4626. PubMed ID: 23651727
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of both paracrine and autocrine VEGF/ VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias.
    Dias S; Hattori K; Heissig B; Zhu Z; Wu Y; Witte L; Hicklin DJ; Tateno M; Bohlen P; Moore MA; Rafii S
    Proc Natl Acad Sci U S A; 2001 Sep; 98(19):10857-62. PubMed ID: 11553814
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TTAC-0001, a human monoclonal antibody targeting VEGFR-2/KDR, blocks tumor angiogenesis.
    Lee WS; Pyun BJ; Kim SW; Shim SR; Nam JR; Yoo JY; Jin Y; Jin J; Kwon YG; Yun CO; Nam DH; Oh K; Lee DS; Lee SH; Yoo JS
    MAbs; 2015; 7(5):957-68. PubMed ID: 25942475
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis.
    Hiratsuka S; Maru Y; Okada A; Seiki M; Noda T; Shibuya M
    Cancer Res; 2001 Feb; 61(3):1207-13. PubMed ID: 11221852
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vascular endothelial growth factor receptor-1 regulates postnatal angiogenesis through inhibition of the excessive activation of Akt.
    Nishi J; Minamino T; Miyauchi H; Nojima A; Tateno K; Okada S; Orimo M; Moriya J; Fong GH; Sunagawa K; Shibuya M; Komuro I
    Circ Res; 2008 Aug; 103(3):261-8. PubMed ID: 18583712
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation.
    Tammela T; Zarkada G; Wallgard E; Murtomäki A; Suchting S; Wirzenius M; Waltari M; Hellström M; Schomber T; Peltonen R; Freitas C; Duarte A; Isoniemi H; Laakkonen P; Christofori G; Ylä-Herttuala S; Shibuya M; Pytowski B; Eichmann A; Betsholtz C; Alitalo K
    Nature; 2008 Jul; 454(7204):656-60. PubMed ID: 18594512
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants.
    Gille H; Kowalski J; Li B; LeCouter J; Moffat B; Zioncheck TF; Pelletier N; Ferrara N
    J Biol Chem; 2001 Feb; 276(5):3222-30. PubMed ID: 11058584
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases.
    Joukov V; Pajusola K; Kaipainen A; Chilov D; Lahtinen I; Kukk E; Saksela O; Kalkkinen N; Alitalo K
    EMBO J; 1996 Jan; 15(2):290-98. PubMed ID: 8617204
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vascular endothelial growth factors encoded by Orf virus show surprising sequence variation but have a conserved, functionally relevant structure.
    Mercer AA; Wise LM; Scagliarini A; McInnes CJ; Büttner M; Rziha HJ; McCaughan CA; Fleming SB; Ueda N; Nettleton PF
    J Gen Virol; 2002 Nov; 83(Pt 11):2845-2855. PubMed ID: 12388821
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Different cascades in the signaling pathway of two vascular endothelial growth factor (VEGF) receptors for the VEGF-mediated murine hepatocellular carcinoma development.
    Yoshiji H; Noguchi R; Kuriyama S; Yoshii J; Ikenaka Y; Yanase K; Namisaki T; Kitade M; Yamazaki M; Uemura M; Fukui H
    Oncol Rep; 2005 May; 13(5):853-7. PubMed ID: 15809749
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vascular endothelial growth factor receptor-1 and receptor-2 initiate a phosphatidylinositide 3-kinase-dependent clonogenic response in acute myeloid leukemia cells.
    List AF; Glinsmann-Gibson B; Stadheim C; Meuillet EJ; Bellamy W; Powis G
    Exp Hematol; 2004 Jun; 32(6):526-35. PubMed ID: 15183893
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of a drug-targetable allosteric site regulating vascular endothelial growth factor signaling.
    Thieltges KM; Avramovic D; Piscitelli CL; Markovic-Mueller S; Binz HK; Ballmer-Hofer K
    Angiogenesis; 2018 Aug; 21(3):533-543. PubMed ID: 29502220
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Placental growth factor neutralising antibodies give limited anti-angiogenic effects in an in vitro organotypic angiogenesis model.
    Brave SR; Eberlein C; Shibuya M; Wedge SR; Barry ST
    Angiogenesis; 2010 Dec; 13(4):337-47. PubMed ID: 20953695
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Unique signal transduction of the VEGF family members VEGF-A and VEGF-E.
    Shibuya M
    Biochem Soc Trans; 2009 Dec; 37(Pt 6):1161-6. PubMed ID: 19909239
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms.
    Huh JI; Calvo A; Stafford J; Cheung M; Kumar R; Philp D; Kleinman HK; Green JE
    Oncogene; 2005 Jan; 24(5):790-800. PubMed ID: 15592523
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma.
    Vacca A; Ria R; Ribatti D; Semeraro F; Djonov V; Di Raimondo F; Dammacco F
    Haematologica; 2003 Feb; 88(2):176-85. PubMed ID: 12604407
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.